콘텐츠로 건너뛰기
Merck
모든 사진(2)

주요 문서

모든 문서 보기

A5602

Sigma-Aldrich

AMD3100 octahydrochloride hydrate

≥97% (NMR), solid, CXCR4 antagonist

동의어(들):

1,1′-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride, JM3100, Plerixafor, SID791

로그인조직 및 계약 가격 보기
모든 사진(2)

About This Item

실험식(Hill 표기법):
C28H54N8 · 8HCl · xH2O
CAS Number:
155148-31-5
Molecular Weight:
794.47 (anhydrous basis)
UNSPSC 코드:
51111800
PubChem Substance ID:
24724394
NACRES:
NA.77

제품명

AMD3100 octahydrochloride hydrate, ≥97% (NMR), solid

Quality Level

100

분석

≥97% (NMR)

양식

solid

저장 조건

desiccated

solubility

H2O: ≥10 mg/mL, clear

주관자

Sanofi Aventis

저장 온도

−20°C

SMILES string

Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].[H]O[H].C1CNCCNCCCN(CCNC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2

InChI

1S/C28H54N8.8ClH.H2O/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H;1H2

InChI key

GKFHDCZYJHUPEN-UHFFFAOYSA-N

애플리케이션

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist. AMD3100 has been used in a study to determine the blockade of CXCR4 in oral squamous cell carcinoma and inhibition of lymph node metastases.

생화학적/생리학적 작용

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist.

특징 및 장점

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

개인 보호 장비

Eyeshields, Gloves, type N95 (US)

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number
056M4602V
115M4607V
053M4615V
012M4618V
090M4614

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

COA 검색

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

David H McDermott et al.
Blood, 123(15), 2308-2316 (2014-02-14)
Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder caused by gain-of-function mutations in the G protein-coupled chemokine receptor CXCR4. The CXCR4 antagonist plerixafor, which is approved by the US Food and Drug Administration (FDA) for stem
Brian A Zabel et al.
Molecular cancer, 10, 73-73 (2011-06-16)
Migration of metastatic tumor cells from the bloodstream into lymph nodes is thought to be facilitated by expression of the chemokine receptors CCR7, CXCR4 and, for B cell-derived tumors, CXCR5. Expression of their respective chemokine ligands (CCL19, CCL21, CXCL12 and
Andreas Lundqvist et al.
Journal of immunology (Baltimore, Md. : 1950), 191(12), 6241-6249 (2013-11-19)
Plerixafor (Mozobil) is a CXCR4 antagonist that rapidly mobilizes CD34(+) cells into circulation. Recently, plerixafor has been used as a single agent to mobilize peripheral blood stem cells for allogeneic hematopoietic cell transplantation. Although G-CSF mobilization is known to alter
Sapna Devi et al.
The Journal of experimental medicine, 210(11), 2321-2336 (2013-10-02)
Blood neutrophil homeostasis is essential for successful host defense against invading pathogens. Circulating neutrophil counts are positively regulated by CXCR2 signaling and negatively regulated by the CXCR4-CXCL12 axis. In particular, G-CSF, a known CXCR2 signaler, and plerixafor, a CXCR4 antagonist
Kelli P A MacDonald et al.
Journal of immunology (Baltimore, Md. : 1950), 192(7), 3180-3189 (2014-03-04)
The majority of allogeneic stem cell transplants are currently undertaken using G-CSF mobilized peripheral blood stem cells. G-CSF has diverse biological effects on a broad range of cells and IL-10 is a key regulator of many of these effects. Using
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.